Exclusive CFN Media Interview: RISE Life Science Study on Cannabis and Sexual Health (Part 2)
July 16th, 2018
Exclusive, News, Top News
CFN Media recently sat down with Dr. Regina Nelson, who is leading a long-term study of sexual health and wellness and how it relates to cannabis for RISE Life Science Corp. (CSE: RLSC). Dr. Nelson is a noted U.S.- based advocate for medical cannabis and author of many peer-reviewed research papers and books on the subject. She is also a founding officer of The eCS Therapy Center, a non-profit organization building awareness of the endocannabinoid system.
Dr. Nelson is working with RISE Life Science to implement a broad and long-term study called ‘The RISE Report on Cannabis and Sexual Health and Wellness’. RISE Life Science is developing and commercializing cannabis-based products for sexual health and wellness. The company is pioneering new and innovative products in an emerging category created by the legalization of cannabis.
This article is Part 2 of a two-story series on her work with Rise Life Science Corp. Click here to read Part 1.
- The protocols for the study are being validated by the Biomedical Research Alliance of New York (BRANY). What is this organization and why is the validation important for the RISE Report?
BRANY is an Institutional Review Board and is reviewing “Sexual Health and Cannabis: A Quantitative and Qualitative Analysis of Consumers of Novel Cannabis Products,” a study which will be published as “The RISE Report.” The IRB validates the study does no harm to human participants. Given the sensitive nature of the subject matter, sexual function and health and cannabis use, an acknowledgement of informed consent will be required for all participants.
The study and questionnaire are expected to receive BRANY Institutional Review Board approval shortly.
- An advisory board has been created for the RISE Report. Who is on it and how will the board assist you?
Yes, the names of those on the Board will be announced shortly. You can expect to see academics, scientists, and other industry leaders.
- How does a study of this type relate to clinical trials for medical products?
This type of study will help us learn more than clinical trials for a specific medical product. At this point in time, millions of people are currently using cannabis products, but no one is talking to them. The data we collect through this study will be meaningful.
- What is the timeline for launching and completing the study? Do you plan to publish the results?
The study will beta-test this summer with a small group of participants. The study will launch in mid-September 2018. Beginning in 2019, participants will be able to view immediate results in many areas and quarterly reports will be released through the RISE Report.
- How can RISE Life Science use this study in its own research and development efforts?
Through this study, RISE will be able to more clearly understand the various factors that affect healthy sexual function and experiences. This study will do that, and it will also help us learn how the introduction of innovative and emerging cannabis products affect sexual experiences, function, and health.
Through this proprietary study RISE will collect information on:
- What sexual function or health concerns are affecting participants
- What experiences are particularly important and why
- How novel cannabis products affect experiences and sexual outcomes
- Specific differences in affect across genders
- Sexual experiences of participants using cannabis products
This is all very valuable to informing product development. The fact that a study of this size has never before been undertaken is significant and it will certainly translate into a competitive advantage for RISE Life Science.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: http://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.